”It’s a slam dunk”
Chapter 6. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. The sixth installment deals with a turning point for daratumumab, which sees bigger companies lining up to partner on the antibody.
BY LONNI LYNGE
After years of climbing a steep clinical mountain, things take a turn for the better in 2010. Jan van de Winkel remembers the first results from studies with daratumumab begin to roll in from the R&D team in the summer of 2010. It turns out that the M component levels in the myeloma proteins begin to drop as daratumumab kills the cancer cells.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Popping the cork
For abonnenter
”It’s a slam dunk”
For abonnenter
Management wants to kill off dara – more than once
For abonnenter
